Apple Inc. vs. Eupraxia Pharmaceuticals Inc. Common Stock
Apple Inc. and Eupraxia Pharmaceuticals Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AAPL | EPRX | |
|---|---|---|
| Market Cap | $4.67 trillion | $555.02 million |
| Revenue (TTM) | $466.82 billion | — |
| Net Income (TTM) | $128.93 billion | — |
AAPL leads on 1 of 1 size & scale factors.
Valuation
| AAPL | EPRX | |
|---|---|---|
| P/E Ratio | 36.69 | — |
| Price / Book | 43.43 | — |
| Price / Sales | 10.00 | — |
AAPL and EPRX split the valuation factors evenly.
Profitability
| AAPL | EPRX | |
|---|---|---|
| Net Margin | 27.62% | — |
| Return on Equity | 119.91% | — |
AAPL and EPRX split the profitability factors evenly.
Dividend
| AAPL | EPRX | |
|---|---|---|
| Dividend Yield | 0.34% | — |
| Payout Ratio | 12.39 | — |
AAPL and EPRX split the dividend factors evenly.
Risk & Sentiment
| AAPL | EPRX | |
|---|---|---|
| Short Interest | 0.31% | 0.01% |
EPRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: AAPL overview, AAPL financials, EPRX overview, EPRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.